中国实用儿科杂志2025，Vol.40Issue(9)：724-728,5.DOI:10.19538/j.ek2025090604
对中国幼年皮肌炎诊断与治疗指南的再认识
Renewed understanding of the diagnosis and treatment guidelines for juvenile dermatomyositis in China
摘要
Abstract
Juvenile Dermatomyositis(JDM)is a chronic autoimmune disease primarily characterized by skin and muscle inflammation,requiring individualized treatment based on disease severity and major organ involved.For non-severe cases,a combination of conventional-dose glucocorticoids with methotrexate serves as the first-line therapy.Methylprednisolone pulse therapy is indicated for severe cases.Recent studies have progressively confirmed the efficacy of intravenous immunoglobulin(IVIG)in JDM.Biological agents and JAK inhibitors may be selectively used for refractory cases,while CAR-T therapy also holds therapeutic promise for these refractory patients.关键词
幼年型皮肌炎/生物制剂/JAK抑制剂/静脉注射免疫球蛋白Key words
juvenile dermatomyositis/biological agents/JAK inhibitors/intravenous immunoglobulin分类
医药卫生引用本文复制引用
何庭艳,杨军..对中国幼年皮肌炎诊断与治疗指南的再认识[J].中国实用儿科杂志,2025,40(9):724-728,5.基金项目
国家重点研发计划项目(2021YFC2702001) （2021YFC2702001）
深圳市三名工程项目(SZSM202411012) （SZSM202411012）
